What AB 1887 does
Summary from the Legislative Counsel's Digest of the enrolled text, September 3, 2026. Read the full text on leginfo.
How it got here
Assemblymember Zbur introduced AB 1887 on . The text was amended 0 times, and heard in 6 committee hearings before its final floor votes.
- Assembly Floor, May 27, 2026: 77 ayes, 0 noes.
Committee votes along the way:
- Assembly Health, April 21, 2026: Do pass and be re-referred to the Committee on [Appropriations], 15-0.
- Assembly Appropriations, May 14, 2026: Do pass., 14-0.
- Senate Health, July 1, 2026: Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations], 10-0.
- Senate Appropriations, August 3, 2026: Placed on suspense file, 7-0.
- Senate Appropriations, August 13, 2026: Do pass as amended, 7-0.
Who supports and opposes AB 1887
The Senate Floor Analyses analysis dated August 24, 2026 lists 40 organizations in support and 3 in opposition. When Assembly Health first listed positions on April 18, 2026, the count was 36 in support and 4 opposed. By the Senate Floor Analyses analysis of August 24, 2026 it was 40 to 3.
In support: California Chronic Care Coalition (sponsor); Arginase 1 Deficiency Foundation; ALS Association; Alliance for Patient Access; Association for Creatine Deficiencies; Biocom California; Bleeding Disorders Council of California; Breathe California; and 32 more.
Opposed: Association of California Life & Health Insurance Companies; California Association of Health Plans; California Chamber of Commerce.
Read the Senate Floor Analyses analysis.
What happens next
It reached the Governor's desk on September 10, 2026. Bills presented after the Legislature adjourned on August 31 must be signed or vetoed within thirty days.
The Governor can sign the bill, veto it, or let it become law without a signature. Until the decision, sign and veto request letters are the remaining channel, and the Department of Finance's enrolled bill report carries weight on anything with a fiscal effect. If signed, most provisions take effect January 1, and implementation moves to the agencies named in the bill.
What it means for pharmaceutical organizations
Two decisions follow from a bill at this stage. The first is whether to weigh in with the Governor's office before the thirty-day window closes. The second is how to prepare for implementation if it becomes law: which agency writes the rules, when the comment period opens, and which obligations begin January 1.
The pharma group at Capitol Axis handles that for pharmaceutical clients.
Questions about AB 1887
What does AB 1887 do?
AB 1887 concerns prescription drug coverage for rare diseases. See the Legislative Counsel's Digest on leginfo for the full summary.
Has AB 1887 passed the California Legislature?
It reached the Governor's desk on September 10, 2026. Bills presented after the Legislature adjourned on August 31 must be signed or vetoed within thirty days.
Who supports and opposes AB 1887?
The Senate Floor Analyses analysis dated August 24, 2026 lists 40 organizations in support and 3 in opposition. Supporters include California Chronic Care Coalition (sponsor); Arginase 1 Deficiency Foundation; ALS Association. Opponents include Association of California Life & Health Insurance Companies; California Association of Health Plans; California Chamber of Commerce.
What happens next with AB 1887?
The Governor can sign it, veto it, or let it become law without a signature. Until then, sign and veto request letters are the remaining channel, and the Department of Finance's enrolled bill report carries weight on anything with a fiscal effect.